Charles Schwab
IRD

Charles Schwab’s Opus Genetics IRD Stock Holding History

Charles Schwab’s Portfolio IRD Stock Details IRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$159K Buy
+35,000
New +$121K ﹤0.01% 3325
2023
Q1 		– Sell
-14,928
Closed -$52.7K – 3599
2022
Q4 		$52.7K Hold
14,928
– – ﹤0.01% 3347
2022
Q3 		$31K Hold
14,928
– – ﹤0.01% 3428
2022
Q2 		$29K Buy
+14,928
New +$33.9K ﹤0.01% 3483

Other funds holding IRD

CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Charles Schwab's IRD Position: Q1 2026 in Review

Charles Schwab opened a new position in Opus Genetics (IRD) in Q1 2026: 35,000 shares worth $159K. The stake represents ﹤0.01% of the portfolio and ranks #3325 among its holdings. This is a return to the name: Charles Schwab previously reported a position in IRD as recently as Q4 2022.

Charles Schwab first reported a position in IRD in Q2 2022 and has held it in 4 quarters since. 79 funds tracked by Wall St. Rank hold IRD as of Q1 2026.

  • Charles Schwab held 35,000 shares of Opus Genetics worth $159K as of Q1 2026.
  • Opus Genetics was a new Charles Schwab position in Q1 2026.
  • Opus Genetics made up ﹤0.01% of Charles Schwab's portfolio in Q1 2026, its #3325 holding.
  • Charles Schwab first reported a position in Opus Genetics in Q2 2022 and has held it in 4 quarters since.
  • 79 funds tracked by Wall St. Rank held Opus Genetics as of Q1 2026.

Based on Charles Schwab's 13F filing for Q1 2026, filed 15 May 2026.